ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Interleukins"

  • Abstract Number: 1197 • ACR Convergence 2024

    Safety and Immunogenicity of an Active Anti-IL-6 Immunotherapy in a Phase 1 Clinical Trial in Knee Osteoarthritis Patients

    François Rannou1, Christelle Nguyen1, Camille Daste1, Quentin Kirren1, marie-martine Lefevre-Colau1, Odile Launay2, Lucille Desallais3, Edita Dolimier3, René Azoulai3, Jean-Pierre Salles3 and Jean-François Zagury4, 1AP-HP. Centre-Université Paris Cité, Hôpital Cochin, Service de Rééducation et de Réadaptation de l'Appareil Locomoteur et des Pathologies du Rachis, Paris, Ile-de-France, France, 2Centre d’Investigation Clinique en Vaccinologie (CIC Cochin Pasteur), Hôpital Cochin, Paris, Ile-de-France, France, 3Peptinov, Paris, Ile-de-France, France, 4Laboratoire Génomique, Bioinformatique, et Chimie Moléculaire, EA 7528, Chaire de Bioinformatique, Conservatoire National des Arts et Métiers, Paris, Ile-de-France, France

    Background/Purpose: Interleukin-6 (IL-6) is a major inflammatory cytokine involved in pain and potentially in osteoarthritis (OA) disease progression. PPV-06 is an IL-6-derived peptide coupled with…
  • Abstract Number: 1385 • ACR Convergence 2024

    A Novel Oral 3D-Printed Delayed- and Extended-Release Tofacitinib (T19) for the Treatment of Rheumatoid Arthritis and Related Inflammatory Diseases

    Yue Zhou, Meng Ji, luo wang, Feihuang Deng, Senping Cheng, Xiaoling Li and Yulian Zhang, Triastek, Inc., Nanjing, China (People's Republic)

    Background/Purpose: Patients with inflammatory diseases, such as rheumatoid arthritis (RA), frequently continue to suffer from morning symptoms despite treatment with conventional therapies 1,2.  Routine morning…
  • Abstract Number: 1462 • ACR Convergence 2024

    Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab versus Subcutaneous IL-17A Inhibitors

    Philip Mease1, Ruizhi Zhao2, Shannon Ferrante3, Natalie J. Shiff4, Pavithra Srinivas5, Soumya Chakravarty6 and Jessica A Walsh7, 1Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 2Janssen Scientific Affairs, LLC, Titusville, NJ, 3Janssen Scientific Affairs, LLC, Horsham, PA, 4Janssen Scientific Affairs, LLC / University of Saskatchewan, Adjunct, Community Health and Epidemiology, Horsham, PA, 5Janssen Scientific Affairs LLC, Horsham, PA, 6Janssen Scientific Affairs, LLC, Horsham/ Drexel University College of Medicine, Philadelphia, Horsham, PA, 7Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT

    Background/Purpose: Guselkumab, a fully human IL-23p19-subunit inhibitor, has demonstrated significant and durable efficacy and high rates of patient retention in randomized controlled trials of adults…
  • Abstract Number: 1464 • ACR Convergence 2024

    Guselkumab and IL-17 Inhibitors Show Comparable Treatment Persistence and Effectiveness in Psoriatic Arthritis: 6-month Interim Results of the PsABIOnd Observational Cohort Study

    Laure Gossec1, Mohamed Sharaf2, Xenofon Baraliakos3, Mitsumasa Kishimoto4, Ennio Lubrano5, Proton Rahman6, Emmanouil Rampakakis7, László Köleséri8, Minni Koivunen9, Frederic Lavie10, Enrique R. Soriano11, Ruben Queiro Silva12, Frank Behrens13 and Stefan Siebert14, 1Sorbonne Université, Paris, France, 2Johnson & Johnson, Middle East FZ LLC, Dubai, UAE, Dubai, United Arab Emirates, 3Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany, 4Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, 5Vincenzo Tiberio Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy, 6Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada, 7McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, 8Data Sciences Staffing Solutions, IQVIA, Inc, Budapest, Hungary, 9Janssen Cilag Oy, Espoo, Finland, Espoo, Finland, 10Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, 11Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 12Rheumatology Division, Hospital Universitario Central de Asturias, Oviedo University School of Medicine, Oviedo, Spain, 13University Hospital Goethe University Frankfurt and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, 14School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Many drugs are available in PsA and have demonstrated efficacy in randomized controlled trials (RCTs); however, real-world long-term data of drugs are scarce. PsABIOnd…
  • Abstract Number: 2344 • ACR Convergence 2024

    Secukinumab Retention and Effectiveness in Patients with Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: 5-year Final Results of a Prospective Real-world Study

    Uta Kiltz1, Petros Sfikakis2, Andreas Bounas3, Nicola Gullick4, Eric LESPESSAILLES5, Jan Brandt Jürgens6, Rasho Rashkov7, Barbara Schulz8, Weibin Bao9, Piotr Jagiello10 and Karl Gaffney11, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, 2Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, 3PRIVATE PRACTICE, Patra, Greece, 4Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, Coventry, United Kingdom, 5CHR ORLEANS, ORLEANS, France, 6Rheumatologische Schwerpunktpraxis, Berlin, Germany, 7Clinic of Rheumatology, University Hospital St. Ivan Rilski, Sofia, Bulgaria, 8GKM Gesellschaft für Therapieforschung mbH, Lessingstrasse, Munchen, Germany, 9Novartis Pharmaceuticals Corporation, East Hanover, NJ, 10Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, 11Health Care - NHS, Norwich, United Kingdom

    Background/Purpose: Real-world data on long-term use of secukinumab complements clinical trial findings by providing insights from diverse patients in routine clinical settings. SERENA (CAIN457A3403) was…
  • Abstract Number: 2355 • ACR Convergence 2024

    Efficacy of Risankizumab Across Distinct PsA Phenotypes Identified with Machine Learning Analytics Using Data from Biologic DMARD-Naive Patients in Two Phase 3 Clinical Trials

    Laure Gossec1, Andra Balanescu2, Maria Antonietta D'Agostino3, Alexis Ogdie4, Philipp Sewerin5, Yu Deng6, Linyu Shi6, Yoshiyuki Sugimoto7, Sheng Zhong6, Yunzhao Xing6, Ralph Lippe6 and Mitsumasa Kishimoto8, 1Sorbonne Université, Paris, France, 2UNIVERSITY OF MEDICINE AND PHARMACY CAROL DAVILA, Bucharest, Romania, 3Versailles-Saint-Quentin University (INSERM U1173, Laboratoire d’Excellence INFLAMEX); University Hospital Ambroise Paré, Versailles, France, 4Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 5Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Bochum, Germany, 6AbbVie Inc., North Chicago, IL, 7AbbVie GK, Tokyo, Tokyo, Japan, 8Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan

    Background/Purpose: Risankizumab (RZB), an IL-23 p19 inhibitor, is well tolerated and provides long-term efficacy through 100 weeks in adults with PsA, demonstrated by the phase…
  • Abstract Number: 2581 • ACR Convergence 2024

    Vunakizumab in Patients with Active Psoriatic Arthritis: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study

    Hejian Zou1, Weiguo Wan2, Yu Xue1, Lingyun Sun3, Ning Zhang4, Haiying Chen5, Xiaofei Shi6, Shengyun Liu7, Lin Chen8, Xinmei Ma9, Hua Wei10, Zhenyu Jiang11, Xiaomei Li12, Hongtao Fan13, Hongbin Li14, Jingyang Li15, Rui Wu16, Guixiu Shi17, Jing Zhu18, Xiaodan Kong19, Yuewu Lu20, Xiaojing Cui21, Qianning Zheng21, Xiaoyan Bai22 and Guangchao Dong21, 1Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, Shanghai, China (People's Republic), 2Huashan Hospital, Fudan University, Shanghai, China (People's Republic), 3Dept of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing Univ Medical School, Nanjing, CN, Nanjing, China (People's Republic), 4Shengjing Hospital Affiliated to China Medical University, Shenyang, China (People's Republic), 5The Third Hospital of Hebei Medical University, Shijiazhuang, China (People's Republic), 6The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China (People's Republic), 7The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China (People's Republic), 8Jilin Province People's Hospital, Changchun, China (People's Republic), 9Zaozhuang Municipal Hospital, Zaozhuang, China (People's Republic), 10Subei People's Hospital of Jiangsu Province, Yangzhou, China (People's Republic), 11The First Hospital of Jilin University, Changchun, China (People's Republic), 12The First Affiliated Hospital of the University of Science and Technology of China, Hefei, China (People's Republic), 13The First People's Hospital of Yunnan Province, Kunming, China (People's Republic), 14Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic), 15Zhuzhou Central Hospital, Zhuzhou, China (People's Republic), 16The Tirst Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China (People's Republic), 17The First Affilated Hospital of Xiamen University, Xiamen, China (People's Republic), 18Sichuan Provincial People's Hospital, Chengdu, China (People's Republic), 19The Second Affiliated Hospital of Dalian Medical University, Dalian, China (People's Republic), 20BeiJing Chao-Yang Hospital, Capital Medical University, Beijing, China, 21Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China (People's Republic), 22Jiangsu Hengrui Pharmaceuticals Co., Ltd., Beijing, China

    Background/Purpose: Patients with psoriasis often develop psoriatic arthritis (PsA), a chronic systemic inflammatory disease with a severe clinical burden that impairs quality of life. In…
  • Abstract Number: 0074 • ACR Convergence 2024

    Tofacitinib Therapy Ameliorates Inflammation in a Mouse Model of Psoriasis and Arthritis by Inducing Type 2 Immunity

    Maria de la Luz Garcia-Hernandez1, Javier Rangel-Moreno1, Ananta Paine2, Angel Rangel-Garcia1, Marissa Krantz3, Delaney Martino1, Marc Nuzzo1 and Christopher Ritchlin4, 1University of Rochester, Rochester, NY, 2ORNA Tx, Southborough, MA, 3University of Rochester, Rochester, NY, 4Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY

    Background/Purpose: Psoriatic arthritis (PsA), a chronic progressive inflammatory arthritis, affects peripheral joints and causes patient disability. PsA patients also have skin plaques initiated by activation…
  • Abstract Number: 2582 • ACR Convergence 2024

    Efficacy and Safety of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Patients with Active PsA: 24-Week Results from a Global, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

    Iain McInnes1, Laura Coates2, Philip Mease3, Alexis Ogdie4, Arthur Kavanaugh5, Lihi Eder6, Georg Schett7, Alan Kivitz8, Nuala Brennan9, Alex Godwood9, Eva Cullen9, Kristian Reich9, Christopher Ritchlin10 and Joseph F. Merola11, 1University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, 2University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, 3Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 4Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 5University of California San Diego, La Jolla, CA, 6University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, 7Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 8Altoona Center for Clinical Research, Duncansville, PA, 9MoonLake Immunotherapeutics AG, Zug, Switzerland, 10Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, 11UT Southwestern Medical Center, Dallas, TX

    Background/Purpose: Sonelokimab is a novel humanized Nanobody designed to inhibit IL-17A and IL-17F and penetrate clinically relevant sites of inflammation. The 24-week Phase 2 ARGO…
  • Abstract Number: 0278 • ACR Convergence 2024

    Efficacy and Safety of Genakumab versus Compound Betamethasone in Gout: The GUARD-1 Study

    Yu Xue1, Tianshu Chu2, Jiankang Hu3, Wei Gou4, Ning Zhang5, Juan Li6, Jing Yu7, Songping Li8, Songbin Li9, Long Qian10, Xinwang Duan11, Lihua Duan12 and Hejian Zou1, 1Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, Shanghai, China (People's Republic), 2Department of Rheumatology, Henan Provincial People's Hospital, Zhengzhou, China, Zhengzhou, China (People's Republic), 3Department of Rheumatology, Pingxiang People's Hospital, Pingxiang, China, Pingxiang, China (People's Republic), 4Department of Rheumatology, Hebei Petro China Central Hospital, Langfang, China, Langfang, China (People's Republic), 5Department of Rheumatology, Shengjing Hospital of China Medical University, Shenyang, China, Shenyang, China (People's Republic), 6Department of Rheumatology, The First Affiliated Hospital of Hainan Medical University, Haikou, China, Haikou, China (People's Republic), 7Department of Rheumatology, The First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China, Shenyang, China (People's Republic), 8Department of Rheumatology, The First Affiliated Hospital of Ganna Medical University, Ganzhou, China, Ganzhou, China (People's Republic), 9Department of Rheumatology, The First Hospital of Qiqihar, Qiqihar, China, Qiqihar, China (People's Republic), 10Department of Rheumatology, The Second Hopital of Anhui Medical University, Hefei, China, Hefei, China (People's Republic), 11Department of Rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, Nanchang, China (People's Republic), 12Department of Rheumatology, Jiangxi Provincial People's Hospital, Nanchang, China, Nanchang, China (People's Republic)

    Background/Purpose: The GUARD (Genakumab in high Uric Acid-induced Arthritis/goutfor Resolution and Delay study) program was designed to investigate the efficacy and safety of Genakumab, a…
  • Abstract Number: 2585 • ACR Convergence 2024

    Guselkumab and IL-17 Inhibitors Improve Patient-perceived Impact of Psoriatic Arthritis Similarly: 6-month Interim Results of the PsABIOnd Observational Cohort Study

    Stefan Siebert1, Mohamed Sharaf2, Carlo Selmi3, Proton Rahman4, Mitsumasa Kishimoto5, Enrique R. Soriano6, Emmanouil Rampakakis7, László Köleséri8, Minni Koivunen9, Frederic Lavie10, Ruben Queiro Silva11, Frank Behrens12, Ennio Lubrano13 and Laure Gossec14, 1School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 2Johnson & Johnson, Middle East FZ LLC, Dubai, UAE, Dubai, United Arab Emirates, 3Department of Biomedical Sciences, Humanitas University, Rozzano, Italy, 4Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada, 5Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, 6Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 7McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, 8Data Sciences Staffing Solutions, IQVIA, Inc, Budapest, Hungary, 9Janssen Cilag Oy, Espoo, Finland, Espoo, Finland, 10Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, 11Rheumatology Division, Hospital Universitario Central de Asturias, Oviedo University School of Medicine, Oviedo, Spain, 12University Hospital Goethe University Frankfurt and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, 13Vincenzo Tiberio Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy, 14Sorbonne Université, Paris, France

    Background/Purpose: PsA leads to significant patient-perceived burden of disease. Targeted drugs have demonstrated efficacy in randomised controlled trials including in aspects of patient-reported impact. However,…
  • Abstract Number: 0303 • ACR Convergence 2024

    Phase 2b, Long-term Extension, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER-2

    Laura K. Ferris1, Jerry Bagel2, Yu-Huei Huang3, Andrew E. Pink4, Stephen K. Tyring5, Georgios Kokolakis6, Amy M. DeLozier7, Daniel Kakaley8, Shu Li9, Yaung-Kaung Shen10, Takayuki Ota7 and Robert Bissonnette11, 1University of Pittsburgh, Pittsburgh, PA, 2Psoriasis Treatment Center of Central NJ, East Windsor, NJ, 3Chang Gung Memorial Hospital and Chang Gung University, Linkou, Taoyuan City, Taiwan (Republic of China), 4NHS Foundation Trust Great Maze Pond, London, United Kingdom, 5Center for Clinical Studies, Webster, TX, 6Psoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 7Janssen Research & Development, LLC, San Diego, CA, 8Janssen Scientific Affairs, LLC, Horsham, PA, 9Janssen Research & Development, LLC, Spring House, PA/San Diego, CA, 10Janssen Research & Development, LLC, Spring House, PA, 11Innovaderm Research, Montreal, QC, Canada

    Background/Purpose: JNJ-77242113, a targeted oral peptide, inhibits IL-23 signaling by binding the IL-23 receptor. At all doses, JNJ-77242113 showed superior efficacy at Week 16 versus…
  • Abstract Number: 2597 • ACR Convergence 2024

    The Stromal-cell Derived Cytokine interleukin-17D Attenuates Joint Inflammation

    Jia (Sijia) Chen1, Roopa Madhu2, Catherine Manning3, Daniel Montoro4, Nataliya Yeremenko5, Kevin Wei6, ilya Korsunsky1, Dominique Baeten5 and Ellen Gravallese7, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Brookline, MA, 3Brigham and Women's Hospital, Dedham, MA, 4TenSixty Biosciences, Boston, MA, 5Amsterdam University Medical Centers, Amsterdam, Netherlands, 6Brigham and Women's Hospital at Harvard Medical School, Boston, MA, 7Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA

    Background/Purpose: The interleukin-17 (IL-17) family of cytokines consists of 6 evolutionarily conserved cytokines, IL-17A-F. Of these, IL-17A, B, C, and F play diverse roles in…
  • Abstract Number: 0562 • ACR Convergence 2024

    Serum Interleukin IL-40 as a Potential Biomarker Associated with Pro-inflammatory Activity in Inflammatory Bowel Diseases and Spondyloarthritis: A Preliminary Study

    Lucia Ondrejčáková1, Adéla Navrátilová2, Monika Gregová3, Kristýna Bubová4, Tomáš Grega5, Ladislav Šenolt6, Karel Pavelka7 and Lucie Andrés Cerezo8, 1Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, 21st Faculty of Medicine, Charles University and Institute of Rheumatology in Prague, Hlavní mesto Praha, Czech Republic, 3Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine Charles University, Prague, Czech Republic, 4Institute of Rheumatology and Charles University, Prague, Czech Republic, 53Department of Internal Medicine, First Faculty of Medicine, Charles University, Military University Hospital, Prague, Czech Republic, Prague, Czech Republic, 6Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 7Institute of Rheumatology and Charles University, Praha, Czech Republic, 8Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic

    Background/Purpose: Interleukin 40 (IL-40) is a novel cytokine with a proposed role in the pathogenesis of inflammatory diseases. Inflammatory bowel diseases (IBD)-associated with spondyloarthritis (SpA)…
  • Abstract Number: 2616 • ACR Convergence 2024

    Associations of Circulating Inflammatory Cytokines with Long COVID Among Patients with Systemic Autoimmune Rheumatic Diseases

    Jeffrey Sparks1, Xiaosong Wang2, Pui Lee3, Kailey Brodeur4, Miao Lin5, Naomi Patel5, Yumeko Kawano6, Abigail Schiff7, Andrew King5, Jennifer Hanberg6, Shruthi Srivatsan5, Emily Kowalski6, Colebrook Johnson5, Kathleen Vanni6, Zachary Williams5, Grace Qian2, Caleb Bolden5, Kevin Mueller6, Katarina Bade6, Alene Saavedra6, Rathnam Venkat8 and Zachary Wallace9, 1Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, 2Brigham and Women’s Hospital, Boston, MA, 3Boston Children's Hospital, Newton, MA, 4Boston Children's Hospital, Cumberland, RI, 5Massachusetts General Hospital, Boston, MA, 6Brigham and Women's Hospital, Boston, MA, 7Brigham and Women's Hospital, Cambridge, MA, 8Tufts University School of Medicine, Boston, MA, 9Massachusetts General Hospital, Newton, MA

    Background/Purpose: While the incidence of severe acute COVID-19 has decreased, post-acute sequelae of COVID-19 characterized by prolonged symptoms, or ‘long COVID,’ is common and associated…
  • 1
  • 2
  • 3
  • …
  • 11
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology